article thumbnail

Waters, as a strategic partner to the pharma industry, can help India become a world leader in biosimilars

Express Pharma

For decades, Waters has been a trusted partner to many pharma and generics companies operating in India, particularly for small molecule QA/QC. India is known as the ‘Pharmacy of the World’, as the generic medicine supplier for over 200 countries, both developed and emerging markets. How poised are you to leverage them?

article thumbnail

Is India capable of ensuring equitable access to biopharmaceuticals?

Express Pharma

In a bid to resolve both physical and financial restrictions inhibiting equitable access to quality medicines, the Jan Aushadhi scheme was launched in 2008 and envisaged the setting up of dedicated Janaushadhi Kendras to provide quality generic medicines at capped prices for the general public.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novartis announces plans to spin off Sandoz business

Pharmaceutical Technology

Novartis has announced plans to completely spin off its generics and biosimilars division, Sandoz, to create a new publicly traded standalone firm. The latest development is intended to increase shareholder value by establishing a top European generics firm and a leader in biosimilars internationally.

article thumbnail

Sandoz to become standalone company

European Pharmaceutical Review

Novartis has announced that it intends to separate Sandoz , its generics and biosimilars division into a new publicly traded standalone company. The 100 percent spin-off aims to establish Sandoz as the premier European generics company and a global leader in biosimilars, maximising shareholder value.

article thumbnail

CHMP meeting highlights: February 2024

European Pharmaceutical Review

Other positive opinions by the CHMP Zynyz* (retifanlimab) as a treatment for Merkel cell carcinoma, a type of skin cancer Pyzchiva (ustekinumab), a biosimilar used to treat plaque psoriasis The generic medicine Apremilast Accord (apremilast), for psoriatic arthritis, psoriasis and Behçet’s disease, a rare type of inflammatory disease Generic medicine (..)

article thumbnail

EMA human medicines committee (CHMP) highlights, November 2022

European Pharmaceutical Review

Four medicines recommended for approval in the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP)’s latest meeting included a biosimilar for osteoporosis and a novel COVID-19 vaccine.

article thumbnail

KFA-115 by Novartis for Melanoma: Likelihood of Approval

Pharmaceutical Technology

The company offers generic medicines and biosimilars through Sandoz. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others.